Karyopharm Therapeutics Inc (NASDAQ: KPTI) is -0.64% lower on its value in year-to-date trading and has touched a low of $0.58 and a high of $1.95 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The KPTI stock was last observed hovering at around $0.62 in the last trading session, with the day’s gains setting it 0.05%.
Currently trading at $0.67, the stock is -0.25% and -6.02% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.01 million and changing 8.44% at the moment leaves the stock -21.69% off its SMA200. KPTI registered -35.38% loss for a year compared to 6-month loss of -22.85%. The firm has a 50-day simple moving average (SMA 50) of $0.71712 and a 200-day simple moving average (SMA200) of $0.86123.
The stock witnessed a -13.84% gain in the last 1 month and extending the period to 3 months gives it a -25.60%, and is 1.76% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.37% over the week and 8.89% over the month.
Karyopharm Therapeutics Inc (KPTI) has around 325 employees, a market worth around $84.80M and $148.44M in sales. Profit margin for the company is -58.93%. Distance from 52-week low is 15.68% and -65.54% from its 52-week high. The company has generated returns on investments over the last 12 months (-282.69%).
with sales reaching $30.29M over the same period.The EPS is expected to grow by 45.03% this year, but quarterly earnings will post 3.01% year-over-year. Quarterly sales are estimated to shrink -10.24% in year-over-year returns.
108.0 institutions hold shares in Karyopharm Therapeutics Inc (KPTI), with institutional investors hold 50.50% of the company’s shares. The shares outstanding are 125.30M, and float is at 116.62M with Short Float at 16.98%. Institutions hold 47.36% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 7.65 million shares valued at $6.64 million. The investor’s holdings represent 6.6299 of the KPTI Shares outstanding. As of 2024-06-30, the second largest holder is PALO ALTO INVESTORS LP with 5.1 million shares valued at $4.43 million to account for 4.4192 of the shares outstanding. The other top investors are EVERSEPT PARTNERS, LP which holds 4.99 million shares representing 4.3196 and valued at over $4.33 million, while ADAGE CAPITAL PARTNERS GP, L.L.C. holds 3.7416 of the shares totaling 4.32 million with a market value of $3.75 million.
Karyopharm Therapeutics Inc (KPTI) Insider Activity
The most recent transaction is an insider sale by Paulson Richard A., the company’s President and CEO. SEC filings show that Paulson Richard A. sold 4,099 shares of the company’s common stock on Feb 04 ’25 at a price of $0.65 per share for a total of $2664.0. Following the sale, the insider now owns 1.12 million shares.
Karyopharm Therapeutics Inc disclosed in a document filed with the SEC on Jan 06 ’25 that Paulson Richard A. (President and CEO) sold a total of 4,055 shares of the company’s common stock. The trade occurred on Jan 06 ’25 and was made at $0.78 per share for $3175.0. Following the transaction, the insider now directly holds 1.12 million shares of the KPTI stock.
Still, SEC filings show that on Dec 04 ’24, Paulson Richard A. (President and CEO) disposed off 3,620 shares at an average price of $0.81 for $2932.0. The insider now directly holds 1,128,312 shares of Karyopharm Therapeutics Inc (KPTI).
